In a finding that could reshape how doctors and patients think about weight-loss medications, a new real-world study suggests that nearly half of people who stop GLP-1 drugs are able to maintain — or even continue — their weight loss.

GLP-1 receptor agonists, widely known through drugs like semaglutide and tirzepatide, have gained global attention for their ability to help people shed significant weight and manage type 2 diabetes. But a key concern has always lingered: what happens when patients stop taking them?

Now, fresh evidence offers a more hopeful picture.

Researchers from the Cleveland Clinic tracked nearly 8,000 adults who had started GLP-1 medications between 2021 and 2023 and discontinued them within 3 to 12 months. The team then followed their progress for a year after stopping treatment.

Before discontinuation, people using these drugs for obesity lost an average of 8.4% of their body weight, while those taking them for type 2 diabetes lost around 4.4%. Surprisingly, a year after stopping, weight regain was minimal.

Participants treated for obesity regained just 0.5% of their weight on average. Meanwhile, those in the diabetes group actually lost an additional 1.3%.

However, the story isn’t one-size-fits-all.

Among those treated for obesity, 55% did regain some weight — but 45% managed to maintain or continue losing weight. In the diabetes group, outcomes were slightly better, with 56% maintaining or reducing weight further.

Experts say this contrasts with earlier clinical trials, where stopping these medications often led to rapid weight regain. The difference, researchers believe, lies in what patients do next.

“In real-world settings, people rarely stop treatment altogether,” explained lead author Hamlet Gasoyan. “Many switch to other therapies, restart medication, or adopt lifestyle changes.”

In fact, within a year of stopping their initial GLP-1 drug, more than a quarter of participants switched to another obesity medication, while 20% restarted their original treatment. Others turned to diet and exercise support, including consultations with nutritionists and fitness experts.

This continued effort may be the key to sustained results.

The findings highlight an important shift in understanding obesity and diabetes management — not as short-term interventions, but as ongoing journeys requiring flexible and personalized strategies.

While the results are encouraging, experts caution that stopping GLP-1 drugs without a follow-up plan may still lead to weight regain. Instead, patients are advised to work closely with their doctors to explore alternative treatments or lifestyle interventions.

As research continues, the message is becoming clearer: GLP-1 drugs may be powerful tools, but long-term success depends on what comes after.